ENDV On The Cusp Of Pre-clinical Testing In $24.5 Billion Liver Disease Market
Good Morning!
ENDV is a hot opportunity in a very developed and proven sector. I am talking about biotech, of course. In the last 10 years no other sector on Wall Street has been as consistent, or delivered as much gains.
Biotech has enjoyed year-to-year growth, outperforming every sector and proving that the smart money knows exactly what it’s doing.
ENDV is a chance to show that you know what trading winners are all about and if you act fast you can secure some of the amazing gain potential being presented by the play.
ENDV is about to start pre-clinical testing for its electroceutical technology. The company made that announcement earlier in the year so the actual start of testing could be breaking news anytime now. Such a development would possibly explode valuation so a move now will allow you to maximize your ROI.
The technical setup almost telegraphs the opportunity. As you’ll see below, this is one of the better entry points for a play that has reached as high as 2.50 in the last 12 months.
ENDV is hot. Biotech is hot, so make your approach swift and effective.
ENDV Must-See Technicals
ENDV has seen an explosion in daily volatility, signalling a surge in interest from investors. The new-found energy means lots of healthy entry/exit opportunities for traders.
RSI of 42 showcases a very strong bounce opportunity for ENDV
ENDV has also been very buoyant since mid-July. It opened big on July 15, reaching a high of .73 for one-day gains of up to 46%.
ENDV has traded as high as 2.50 in the last 12 months. The current upside opportunity from present valuation is over 410%.
ENDV is also trading below its 50 DMA of .75 which presents short-term upside opportunity of more than 48%.
About ENDV
ENDV (Endonovo Therapeutics, Inc.) is a biotechnology company which develops cell-based therapies and non-invasive bio-electronic therapies to enhance the human life through regenerating tissues and organs.
ENDV is developing therapies for various inflammatory, autoimmune, and degenerative diseases using cell therapies and time-varying electromagnetic fields.
Global Liver Treatment Market Was $24.5 Billion In 2014
Globally, liver disease treatment market is growing with moderate growth rate due to aging population, excessive alcohol consumptions and increasing prevalence of liver diseases. Moreover, high unmet needs for the treatment of liver cancer also supports in growth of liver disease treatment market.
The global liver diseases treatment market totaled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate (CAGR) of 6.7% through 2019.
Big News Development
Endonovo Therapeutics Targets Non-Invasive Treatment for Acute and Chronic Inflammatory Conditions of the Liver
In April ENDV announced plans to begin pre-clinical testing of its electroceutical technology to treat and reverse acute and chronic inflammatory liver pathologies. This includes the conditions that cause non-alcoholic steatohepatitis (NASH) and human cirrhotic liver disease.
The American Liver Foundation estimates that up to 30% of the U.S. population is affected by non-alcoholic fatty liver diseases, including NASH and other obesity related liver ailments.
To learn more about ENDV please visit their website: http://endonovo.com/
Since delivering 46% intraday gains back in July, ENDV has pulled back nicely. This presents a huge bounce opportunity for traders right now and with momentum moving as it is, the explosion could be even bigger than 46%.
Make your move on ENDV right now.
